All data are based on the daily closing price as of July 19, 2024
a

Alar Pharmaceuticals

6785.TWO
6.09 USD
-0.36
-5.58%

Overview

Last close
6.09 usd
Market cap
406.75M usd
52 week high
14.60 usd
52 week low
3.77 usd
Target price
N/A usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
N/A
Price/Book Value
N/A
Enterprise Value
N/A usd
EV/Revenue
N/A
EV/EBITDA
N/A

Key financials

Revenue TTM
N/A usd
Gross Profit TTM
N/A usd
EBITDA TTM
N/A usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
N/A usd
Net debt
N/A usd

About

Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. It is developing ALA-1000, which is in Phase II clinical trials for the treatment of opioid use disorder; ALA-1300 and ALA-2000, which is in pre-clinical stage for opioid use disorder; ALA-4000 which is in pre-clinical stage for treatment of Parkinson's disease; and ALA-3000, which is in pre-clinical stage for treating treatment-resistant depression. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.
  • Symbol
    6785.TWO
  • Exchange
    TWO
  • Isin
    N/A
  • Country
    Taiwan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
    Dr. Yung-Shun Wen Ph.D.
  • Headquarter
    Taichung
  • Web site
    https://www.alarpharm.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top